Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359 | 0.72 | CYP1A2 (0.46) | NCF1MAPTALDH1A1HPGDGLA | |
| SCHEMBL529979 | 0.72 | POLB (0.49) | MAPTALDH1A1CYP1A2LMNAKDM4E | |
| SCHEMBL269764 | 0.68 | ALDH1A1 (0.42) | NCF1MAPTALDH1A1HPGDGLA | |
| SCHEMBL466391 | 0.68 | ALDH1A1 (0.42) | NCF1MAPTALDH1A1HPGDGLA | |
| SCHEMBL4717309 | 0.68 | NCF1 (0.46) | NCF1MAPTALDH1A1HPGDGLA | |
| SCHEMBL529257 | 0.68 | ALDH1A1 (0.42) | NCF1MAPTALDH1A1HPGDGLA | |
| SCHEMBL178081 | 0.68 | TLR8 (0.42) | NCF1MAPTALDH1A1HPGDGLA | |
| SCHEMBL5748142 | 0.68 | NCF1 (0.39) | NCF1MAPTALDH1A1HPGDGLA | |
| SCHEMBL21195879 | 0.68 | CYP1A2 (0.42) | NCF1MAPTALDH1A1HPGDGLA | |
| SCHEMBL9870736 | 0.65 | ALDH1A1 (0.43) | NCF1MAPTALDH1A1HPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | claimed |
| EP-2023728-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2009-02-18 | — | — | EP | claimed |
| WO-2007140005-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | WO | claimed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2023728-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2009-02-18 | — | — | EP | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007140005-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | NCF1 4127/4885MAPT 2871/4885ALDH1A1 347/4885 |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | FAAH, FAAH2, APEH | NCF1 2779/4885MAPT 2537/4885ALDH1A1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.